Key statistics
As of last trade Oculis Holding AG (CR5:FRA) traded at 11.00, -12.70% below its 52-week high of 12.60, set on Jan 31, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.00 |
---|---|
High | 11.00 |
Low | 11.00 |
Bid | 13.30 |
Offer | 14.80 |
Previous close | 11.00 |
Average volume | -- |
---|---|
Shares outstanding | 41.75m |
Free float | 38.53m |
P/E (TTM) | -- |
Market cap | 614.49m USD |
EPS (TTM) | -2.01 USD |
Data delayed at least 15 minutes, as of Oct 08 2024 08:59 BST.
More ▼
- Oculis to Present at the Stifel 2024 Healthcare Conference
- Oculis Reports Q3 2024 Financial Results and Provides Company Updates
- Oculis birtir uppgjör fyrir þriðja ársfjórðung 2024 og kynnir nýjustu áfanga í rekstri félagsins
- Oculis Accelerates Enrollment in both DIAMOND Phase 3 Trials of OCS-01 in Diabetic Macular Edema and Expands its DIAMOND Program Committees
- Oculis Announces Appointment of Daniel S. Char as Chief Legal Officer
- Oculis Publishes Consolidated Q2 Financial Statements and MD&A
- Oculis birtir uppgjör fyrir annan ársfjórðung 2024 og kynnir nýjustu áfanga í rekstri félagsins
- Oculis Reports Q2 Financial Results and Provides Recent Company Update
- Oculis Appoints Sharon Klier, M.D., M.S., M.P.H. as Chief Development Officer
- Oculis Announces Positive Topline Results of Phase 2b RELIEF Trial with Licaminlimab, Designed to Transform the Treatment Paradigm of Dry Eye Disease with a Precision Medicine Strategy
More ▼